Holen Sie sich die Stockscreener-App
272.61
0.05%
-0.13
Handel nachbörslich:
272.61
Schlusskurs vom Vortag:
$272.74
Offen:
$276.66
24-Stunden-Volumen:
249.51K
Relative Volume:
0.85
Marktkapitalisierung:
$7.91B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
91.17
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
-3.42%
1M Leistung:
+4.28%
6M Leistung:
+96.60%
1J Leistung:
+76.03%
1-Tages-Spanne:
$270.00
$280.00
1-Wochen-Bereich:
$258.34
$286.52
52-Wochen-Spanne:
$122.80
$295.98
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
272.61 | 7.91B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech wins FDA RMAT status for lung cancer therapy - Seeking Alpha
Krystal Biotech (KRYS) Gains FDA RMAT Status for Innovative Lung Cancer Therapy - GuruFocus
Krystal Biotech Says US FDA Grants Regenerative Medicine Advanced Therapy Designation to Lung Cancer Treatment - marketscreener.com
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy By Investing.com - Investing.com India
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of ... - Caledonian Record
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer - The Manila Times
FDA backs KB707 lung cancer immunotherapy with RMAT designation - stocktitan.net
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - MSN
Federated Hermes Inc. Cuts Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision - Insider Monkey
Krystal Biotech (BIT:1KRYS) Price Target Increased by 11.47% to 252.42 - Nasdaq
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline - Sahm
Goldman Sachs Raises Price Target for Krystal Biotech (KRYS) | K - GuruFocus
Atle Fund Management AB Acquires 22,033 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech stock price target raised to $327 by Goldman Sachs - Investing.com Canada
Earnings Miss: Is Krystal Biotech Inc. impacted by rising ratesJuly 2025 Short Interest & Safe Entry Point Alerts - mfd.ru
Krystal Biotech, Inc. $KRYS Shares Acquired by EFG Asset Management North America Corp. - MarketBeat
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Clear Street raises Krystal Biotech stock price target on KB801 potential - Investing.com Canada
Are you looking for a top momentum pick? Why Krystal Biotech, Inc. (KRYS) is a great choice - MSN
Assessing Krystal Biotech (KRYS) Valuation As Analyst Upgrades And Earnings Optimism Gain Traction - Sahm
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice - Yahoo Finance
Krystal Biotech, Inc. $KRYS Shares Sold by Maryland State Retirement & Pension System - MarketBeat
SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Bank of America Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $318.00 - MarketBeat
KRYS Sees New Price Target as B of A Securities Raises Outlook | - GuruFocus
BofA Securities Adjusts Price Target on Krystal Biotech to $318 From $288, Maintains Buy Rating - marketscreener.com
Nasdaq Moves: Is Caribou Biosciences Inc. backed by strong institutional buyingSell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Rate Cut: What drives Krystal Biotech Incs stock price2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What does Wall Street think about Krystal Biotech (KRYS)? - MSN
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
What Does Wall Street Think About Krystal Biotech (KRYS)? - Finviz
Krystal Biotech (KRYS) Is Up 9.0% After Positive Interim Data From Inhaled CF Gene Therapy Study - Sahm
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Assessing Krystal Biotech (KRYS) Valuation After Strong Recent Share Price Momentum - Sahm
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Krystal Biotech Reports Strong Q3 2025 Performance - MSN
Krystal Biotech rises on new phase 1 data for cystic fibrosis asset - MSN
Activity Recap: Will Krystal Biotech Inc outperform small cap indexes2025 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Krystal Biotech (KRYS) Price Target Increased by 18.96% to 269.93 - Nasdaq
Krystal Biotech (BIT:1KRYS) Price Target Increased by 19.80% to 226.45 - Nasdaq
Movement Recap: What is Krystal Biotech Inc.’s market position2025 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - sharewise.com
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price - MarketBeat
Avoiding Lag: Real-Time Signals in (KRYS) Movement - Stock Traders Daily
Krystal Biotech stock maintains Buy rating at H.C. Wainwright on strong revenue - Investing.com Canada
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
7.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):